

**SPEAKER:** Well, I think the uptake of PCSK9 inhibition for patients who are prescribed the therapy in Germany has been very good. So the experience versus how patients tolerate the treatment probably has even been better than this statin therapy. And I think one of the, of course, implications of the PCSK9 data is also that we need to get better to really implement intense statin therapy in the majority of our patients.

But a PCSK9 inhibition, because it has not been associated with a discussion on muscle symptoms and so on, like we have always in the statin treated patients, has been barely taken up in the clinical setting.